PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
Completed · Phase 1 · NCT06299410
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $674,740
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 58
About the trial
- Sponsor
- Intra-Cellular Therapies, Inc.
- Tested
- ITI-1284 10 mg (drug), ITI-1284 20 mg (drug)
- Dates
- Started 2024-04-11; completion 2026-08-18
- Results posted
- Not yet
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) reported $674,740 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $674,740
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.